PL375740A1 - Rekombinowany pokswirus zawierający przynajmniej dwa promotory ATI wirusa ospy krowiej - Google Patents

Rekombinowany pokswirus zawierający przynajmniej dwa promotory ATI wirusa ospy krowiej

Info

Publication number
PL375740A1
PL375740A1 PL03375740A PL37574003A PL375740A1 PL 375740 A1 PL375740 A1 PL 375740A1 PL 03375740 A PL03375740 A PL 03375740A PL 37574003 A PL37574003 A PL 37574003A PL 375740 A1 PL375740 A1 PL 375740A1
Authority
PL
Poland
Prior art keywords
seq
recombinant poxvirus
nucleotides
promoter
cowpox ati
Prior art date
Application number
PL03375740A
Other languages
English (en)
Inventor
Sonja Leyrer
Paul Howley
Original Assignee
Bavarian Nordic A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bavarian Nordic A/S filed Critical Bavarian Nordic A/S
Publication of PL375740A1 publication Critical patent/PL375740A1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/863—Poxviral vectors, e.g. entomopoxvirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/60—Vector systems having a special element relevant for transcription from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
PL03375740A 2002-11-25 2003-11-12 Rekombinowany pokswirus zawierający przynajmniej dwa promotory ATI wirusa ospy krowiej PL375740A1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA200201814 2002-11-25

Publications (1)

Publication Number Publication Date
PL375740A1 true PL375740A1 (pl) 2005-12-12

Family

ID=32337938

Family Applications (1)

Application Number Title Priority Date Filing Date
PL03375740A PL375740A1 (pl) 2002-11-25 2003-11-12 Rekombinowany pokswirus zawierający przynajmniej dwa promotory ATI wirusa ospy krowiej

Country Status (21)

Country Link
US (1) US7300658B2 (pl)
EP (1) EP1567653B1 (pl)
JP (1) JP2006515170A (pl)
KR (1) KR20050083839A (pl)
CN (1) CN1717488A (pl)
AT (1) ATE365220T1 (pl)
AU (1) AU2003293675B2 (pl)
CA (1) CA2501168A1 (pl)
CY (1) CY1106883T1 (pl)
DE (1) DE60314541T2 (pl)
DK (1) DK1567653T3 (pl)
EA (1) EA012723B1 (pl)
ES (1) ES2288634T3 (pl)
IL (1) IL167844A (pl)
MX (1) MXPA05005549A (pl)
NO (1) NO20053125D0 (pl)
NZ (1) NZ540156A (pl)
PL (1) PL375740A1 (pl)
PT (1) PT1567653E (pl)
UA (1) UA85379C2 (pl)
WO (1) WO2004048582A2 (pl)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ524661A (en) * 2000-11-23 2005-03-24 Bavarian Nordic As Modified vaccinia ankara virus variant
US7501127B2 (en) 2002-05-16 2009-03-10 Bavarian Nordic A/S Intergenic regions as novel sites for insertion of HIV DNA sequences in the genome of Modified Vaccinia virus Ankara
EA007811B1 (ru) * 2002-05-16 2007-02-27 Бавариан Нордик А/С Межгенные области, используемые в качестве инсерционных сайтов в геноме модифицированного вируса коровьей оспы анкара (mva)
EP2426142A3 (en) 2006-10-16 2012-06-13 Genelux Corporation Modified vaccinia virus strains for use in a diagnostic and therapeutic method
US20110052627A1 (en) * 2008-06-20 2011-03-03 Paul Chaplin Recombinant modified vaccinia virus measles vaccine
JP2012509073A (ja) 2008-11-21 2012-04-19 バヴァリアン・ノルディック・アクティーゼルスカブ 複数の相同ヌクレオチド配列を含むベクター
US8394385B2 (en) * 2009-03-13 2013-03-12 Bavarian Nordic A/S Optimized early-late promoter combined with repeated vaccination favors cytotoxic T cell response against recombinant antigen in MVA vaccines
WO2013115884A2 (en) * 2011-11-15 2013-08-08 Trustees Of Boston University Pyridopyrimidinone inhibitors of viruses
WO2016115116A1 (en) 2015-01-12 2016-07-21 Geovax, Inc. Compositions and methods for generating an immune response to a hemorrhagic fever virus
KR20160140075A (ko) 2015-05-29 2016-12-07 코오롱생명과학 주식회사 폭스바이러스 유래 프로모터 및 이를 포함하는 벡터
FR3042121A1 (fr) 2015-10-08 2017-04-14 Jean-Marc Limacher Composition anti-tumorale
BR112018010639A2 (pt) * 2015-11-24 2019-01-22 Glaxosmithkline Ip Dev Ltd método de transfecção transitória para produção retroviral.
EP3380604B1 (en) * 2015-11-24 2022-12-28 GlaxoSmithKline Intellectual Property Development Limited Stable cell lines for retroviral production
EP3402802B1 (en) 2016-01-08 2023-04-12 Geovax, Inc. Compositions and methods for generating an immune response to a tumor associated antigen
BR112018015696A2 (pt) 2016-02-03 2018-12-26 Geovax Inc composições e métodos para gerar uma resposta imune para um flavivírus
KR20230113832A (ko) * 2016-08-09 2023-08-01 시티 오브 호프 키메라 폭스바이러스 조성물 및 이의 용도
US11311612B2 (en) 2017-09-19 2022-04-26 Geovax, Inc. Compositions and methods for generating an immune response to treat or prevent malaria

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5443964A (en) * 1987-08-10 1995-08-22 Duke University Poxvirus insertion/expression vector
US5759841A (en) * 1990-11-20 1998-06-02 Virogenetics Corporation Immunological composition of measles virus utilizing recombinant poxvirus
UA68327C2 (en) * 1995-07-04 2004-08-16 Gsf Forschungszentrum Fur Unwe A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals
AU4556597A (en) * 1996-09-24 1998-04-17 Bavarian Nordic Research Institute A/S Recombinant mva virus expressing dengue virus antigens, and the use thereof in vaccines
US6682742B1 (en) * 1999-05-28 2004-01-27 Gsf Forschungszentrum Fur Unwelt Und Gesundheit Gmbh Vector for integration of heterologous sequences into poxviral genomes
US7034141B2 (en) 2000-08-29 2006-04-25 Wyeth Holdings Corporation Packaging of positive-strand RNA virus replicon particles

Also Published As

Publication number Publication date
UA85379C2 (ru) 2009-01-26
JP2006515170A (ja) 2006-05-25
CN1717488A (zh) 2006-01-04
PT1567653E (pt) 2007-10-01
CY1106883T1 (el) 2012-09-26
EP1567653B1 (en) 2007-06-20
EA200500879A1 (ru) 2005-10-27
NO20053125L (no) 2005-06-24
AU2003293675B2 (en) 2009-04-23
DK1567653T3 (da) 2007-10-15
EP1567653A2 (en) 2005-08-31
EA012723B1 (ru) 2009-12-30
DE60314541D1 (de) 2007-08-02
KR20050083839A (ko) 2005-08-26
US7300658B2 (en) 2007-11-27
WO2004048582A3 (en) 2004-08-12
AU2003293675A1 (en) 2004-06-18
NO20053125D0 (no) 2005-06-24
NZ540156A (en) 2006-11-30
ATE365220T1 (de) 2007-07-15
IL167844A (en) 2011-03-31
ES2288634T3 (es) 2008-01-16
WO2004048582A2 (en) 2004-06-10
CA2501168A1 (en) 2004-06-10
DE60314541T2 (de) 2008-02-28
MXPA05005549A (es) 2005-08-16
US20060153874A1 (en) 2006-07-13

Similar Documents

Publication Publication Date Title
NO20053125D0 (no) Rekombinant koppevirus omfattende i det minste to kukoppe-ati-promotere.
JP2001081042A5 (pl)
UA82998C2 (ru) Экспрессия генов в модифицированном вирусе коровьей оспы ankara с использованием коровьего поксвирусного промотора аті
US6869793B2 (en) Recombinant MVA virus expressing dengue virus antigens, and the use thereof in vaccines
IL204539A (en) Foxvirus virus containing defective genes and a losing gene
JP2003523721A5 (pl)
IL193088A (en) Recombinant Vasinia Ankara virus (mva) expressing homologous genes inserted into the mva genome
NZ592082A (en) Promoters for recombinant viral expression
PH12021550029A1 (en) Adenovirus-vectored vaccine for preventing sars-cov-2 infection
WO2001089559A3 (en) Porcine reproductive and respiratory syndrome virus (prrsv) recombinant avipoxvirus vaccine
CN101142319B (zh) 基于使用修饰安卡拉痘苗病毒的疫苗
MXPA02005525A (es) Clones infecciosos.
BR0012512A (pt) Genes de calicivìrus felino e vacinas notadamente vacinas recombinadas
IL164179A0 (en) Expression of genes in modified vaccinia virus ankara by using the cowpox ati promoter
CA2372709A1 (en) Vector for integration of heterologous sequences into poxviral genomes
WO2003040305A3 (en) Porcine adenovirus e1 and e4 regions
HK1055762A1 (en) Generation of human cytomegalovirus yeast artificial chromosome recombinants
NZ331063A (en) Isolated nucleotide sequences encoding for mature LS- DNase which is resistant to actin inhibition
JPWO2021154828A5 (pl)
JP2009232836A5 (pl)
NZ507942A (en) Viral chimeras comprised of CAEV and HIV-1 genetic elements
DK200201813A (da) Ekspression af gener i modificeret vaccinia virus ankara ved brug af ATI promotoren fra ko-kopper
BR0316553A (pt) Poxvìrus recombinante que compreende pelo menos dois promotores ati de varìola bovina

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)